Shang-Mian Yie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Shang-Mian Yie has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Shang-Rong Ye
Chengdu Bioengineering Institute for Cancer Research
8 shared publicationsDan-Dan Dong
Sichuan Provincial People’s Hospital
4 shared publicationsHong Yang
Sichuan Provincial People’s Hospital
4 shared publicationsKe Li
Sichuan Provincial People’s Hospital
4 shared publicationsMei Cao
Core Laboratory, Sichuan Academy of Medical Sciences
4 shared publicationsXu He
Core Laboratory, Sichuan Academy of Medical Sciences, Chengdu, Sichuan, People's Republic of China
4 shared publications
Latest Publications
- Open Access
- 11 March 2015
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 35 (5) , 1219-1229
Stem cells derived from human first-trimester umbilical cord have the potential to differentiate into oocyte-like cells in vitro
Compared to stem cells derived from human term umbilical cord, stem cells derived from human first-trimester umbilical cord (hFTUC) exhibit a significantly greater proliferative potential, and more efficiency in terms of their in vitro differentiation. In the present study, we investigated whether hFTUC-derived stem cells are able to differentiate into germ cells. The hFTUC-derived stem cells were first isolated, expanded and then cultured in differentiation medium containing human follicular fluid, follicle-stimulating hormone (FSH)/luteinizing hormone (LH) and estradiol for 24 days. During the period of induction, a subpopulation of the cultured cells appeared that had a morphological resemblance to primordial germ cells (PGCs) and cumulus-oocyte complex (COC)-like cells, and oocyte-like cells (OLCs). The PGC-like cells expressed specific markers indicative of germ cell formation such as octamer-binding transcription factor 4 (OCT4), stage-specific embryonic antigen 1 (SSEA1), B lymphocyte-induced maturation protein-1 (Blimp1), PR domain containing 14 (Prdm14), transcription factor AP-2 gamma (Tfap2C), VASA, STELLA, deleted in azoospermia-like (DAZL) and interferon-induced transmembrane protein 3 (IFITM3). The OLCs, which contained a single germinal vesicle, expressed oocyte-specific markers, such as synaptonemal complex protein 3 (SCP3), growth/differentiation factor-9 (GDF9), GDF9B and zona pellucida (ZP)1, ZP2 and ZP3. The COC-like cells secreted estradiol, vascular endothelial growth factor and leukemia inhibitory factor. Thus, our findings suggest that hFTUC-derived stem cells have an intrinsic ability to differentiate into OLCs, which may provide an in vitro model for the identification of factors involved in germ cell formation and differentiation.
- 11 March 2015
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 35 (5) , 1219-1229
Open AccessStem cells derived from human first-trimester umbilical cord have the potential to differentiate into oocyte-like cells in vitro
Compared to stem cells derived from human term umbilical cord, stem cells derived from human first-trimester umbilical cord (hFTUC) exhibit a significantly greater proliferative potential, and more efficiency in terms of their in vitro differentiation. In the present study, we investigated whether hFTUC-derived stem cells are able to differentiate into germ cells. The hFTUC-derived stem cells were first isolated, expanded and then cultured in differentiation medium containing human follicular fluid, follicle-stimulating hormone (FSH)/luteinizing hormone (LH) and estradiol for 24 days. During the period of induction, a subpopulation of the cultured cells appeared that had a morphological resemblance to primordial germ cells (PGCs) and cumulus-oocyte complex (COC)-like cells, and oocyte-like cells (OLCs). The PGC-like cells expressed specific markers indicative of germ cell formation such as octamer-binding transcription factor 4 (OCT4), stage-specific embryonic antigen 1 (SSEA1), B lymphocyte-induced maturation protein-1 (Blimp1), PR domain containing 14 (Prdm14), transcription factor AP-2 gamma (Tfap2C), VASA, STELLA, deleted in azoospermia-like (DAZL) and interferon-induced transmembrane protein 3 (IFITM3). The OLCs, which contained a single germinal vesicle, expressed oocyte-specific markers, such as synaptonemal complex protein 3 (SCP3), growth/differentiation factor-9 (GDF9), GDF9B and zona pellucida (ZP)1, ZP2 and ZP3. The COC-like cells secreted estradiol, vascular endothelial growth factor and leukemia inhibitory factor. Thus, our findings suggest that hFTUC-derived stem cells have an intrinsic ability to differentiate into OLCs, which may provide an in vitro model for the identification of factors involved in germ cell formation and differentiation.
- 5 July 2011
- Published by Wiley in Tissue Antigens
- Vol. 78 (2) , 120-128
Plasma soluble HLA‐G is a potential biomarker for diagnosis of colorectal, gastric, esophageal and lung cancer
Human leukocyte antigen‐G (HLA‐G) is a novel tumor marker and its soluble isoforms produce secretory proteins. Increased soluble HLA‐G (sHLA‐G) levels have been reported in patients with melanoma, neuroblastoma, lymphoproliferative disorders, breast, ovarian and colorectal carcinoma when compared to healthy controls or subjects with benign neoplasms. The aim of this study is to investigate whether or not plasma sHLA‐G can be used as a potential biomarker for cancer diagnosis. We measured plasma sHLA‐G levels in 166 patients with early stages of colorectal cancer (CRC, n = 37), gastric cancer (GC, n = 28), esophageal squamous cell carcinoma (ESCC, n = 58) and non‐small cell lung cancer (NSCLC, n = 43), and compared them to healthy controls (n = 260) by using a specific HLA‐G enzyme‐linked immunosorbent assay (ELISA). We found that plasma sHLA‐G levels were significantly higher in cancer patients than in healthy controls (all P < 0.0001). The areas under the receiver‐operating characteristic (ROC) curves for sHLA‐G were 0.97, 0.91, 0.98 and 0.80 for healthy controls vs CRC, GC, ESCC and NSCLC, respectively. At 100% specificity, the highest sensitivity achieved to detect CRC, GC, ESCC and NSCLC was 94% [95% confidence interval (CI), 89–99], 85% (95% CI, 76–94), 91% (95% CI, 88–94) and 51% (95% CI, 43–59) at a cutoff value of 49 U/ml, respectively. These findings suggest that plasma sHLA‐G may be a useful molecule in the differential diagnosis of these malignancies against healthy controls.
- 5 July 2011
- Published by Wiley in Tissue Antigens
- Vol. 78 (2) , 120-128
Plasma soluble HLA‐G is a potential biomarker for diagnosis of colorectal, gastric, esophageal and lung cancer
Human leukocyte antigen‐G (HLA‐G) is a novel tumor marker and its soluble isoforms produce secretory proteins. Increased soluble HLA‐G (sHLA‐G) levels have been reported in patients with melanoma, neuroblastoma, lymphoproliferative disorders, breast, ovarian and colorectal carcinoma when compared to healthy controls or subjects with benign neoplasms. The aim of this study is to investigate whether or not plasma sHLA‐G can be used as a potential biomarker for cancer diagnosis. We measured plasma sHLA‐G levels in 166 patients with early stages of colorectal cancer (CRC, n = 37), gastric cancer (GC, n = 28), esophageal squamous cell carcinoma (ESCC, n = 58) and non‐small cell lung cancer (NSCLC, n = 43), and compared them to healthy controls (n = 260) by using a specific HLA‐G enzyme‐linked immunosorbent assay (ELISA). We found that plasma sHLA‐G levels were significantly higher in cancer patients than in healthy controls (all P < 0.0001). The areas under the receiver‐operating characteristic (ROC) curves for sHLA‐G were 0.97, 0.91, 0.98 and 0.80 for healthy controls vs CRC, GC, ESCC and NSCLC, respectively. At 100% specificity, the highest sensitivity achieved to detect CRC, GC, ESCC and NSCLC was 94% [95% confidence interval (CI), 89–99], 85% (95% CI, 76–94), 91% (95% CI, 88–94) and 51% (95% CI, 43–59) at a cutoff value of 49 U/ml, respectively. These findings suggest that plasma sHLA‐G may be a useful molecule in the differential diagnosis of these malignancies against healthy controls.
- 1 March 2011
- Vol. 26 (3) , 409-20
Human leukocyte antigen-G (HLA-G) as a marker for diagnosis, prognosis and tumor immune escape in human malignancies.
Human leukocyte antigen-G (HLA-G) is a non-classical HLA-class Ib molecule with multiple immunoregulatory properties. Its main functions in physiological conditions are to abolish maternal immune cell activity against fetus and to establish immune tolerance at the maternal-fetal interface. In oncology, HLA-G molecules are aberrantly expressed in a variety of human neoplastic diseases and play an important role in the escape of tumor cells from immune surveillance. In the past few years, making use of HLA-G protein expression in tissues and circulating levels in body fluids as a tumor marker have been the focus of extensive research in the diagnosis and prognosis of several human malignancies. In addition, this molecule might be a promising target for future immune therapeutic approaches based on its immune tolerant functions and its highly specific expression for malignant transformation. In this review, we will summarize available literature data as well as our own works on HLA-G in cancer, and address some of the issues concerning its application in human neoplasia.
- 1 March 2011
- Vol. 26 (3) , 409-20
Human leukocyte antigen-G (HLA-G) as a marker for diagnosis, prognosis and tumor immune escape in human malignancies.
Human leukocyte antigen-G (HLA-G) is a non-classical HLA-class Ib molecule with multiple immunoregulatory properties. Its main functions in physiological conditions are to abolish maternal immune cell activity against fetus and to establish immune tolerance at the maternal-fetal interface. In oncology, HLA-G molecules are aberrantly expressed in a variety of human neoplastic diseases and play an important role in the escape of tumor cells from immune surveillance. In the past few years, making use of HLA-G protein expression in tissues and circulating levels in body fluids as a tumor marker have been the focus of extensive research in the diagnosis and prognosis of several human malignancies. In addition, this molecule might be a promising target for future immune therapeutic approaches based on its immune tolerant functions and its highly specific expression for malignant transformation. In this review, we will summarize available literature data as well as our own works on HLA-G in cancer, and address some of the issues concerning its application in human neoplasia.
- 6 January 2010
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 17 (5) , 1459-1469
HLA-G Expression in Human Breast Cancer: Implications for Diagnosis and Prognosis, and Effect on Allocytotoxic Lymphocyte Response After Hormone Treatment In Vitro
The aim of this study is to investigate clinical implications of human leukocyte antigen-G (HLA-G) expression in breast cancer. HLA-G expression in 235 primary breast cancer tissues was investigated using immunohistochemistry, and plasma soluble HLA-G (sHLA-G) was measured in 44 breast cancer patients using a specific HLA-G enzyme-linked immunosorbent assay (ELISA). Effects of estradiol/progesterone and their antagonists tamoxifen/RU486 on HLA-G expression in cultured breast cancer MCF-7 cells were determined by real-time polymerase chain reaction (PCR) and the ELISA. Alterations of HLA-G expression by the hormone treatments on subsequent allocytotoxic lymphocyte (allo-CTL) response were also examined. In the study, approximately 66% of neoplasm lesions were identified to have positive HLA-G expression. This expression was significantly correlated with tumor size, nodal status, and clinical disease stage (P = 0.0001, 0.012, and 0.0001, respectively). Patients with positive HLA-G expression had a lower survival rate than those with negative expression (P < 0.028). Plasma sHLA-G levels were significantly higher in breast cancer patients than in healthy controls (P < 0.001), with the area under the receiver-operating characteristic (ROC) curve being 0.95. HLA-G expression in breast cancer MCF-7 cells was enhanced by estradiol/progesterone but reduced by their antagonists. Cytotoxicity studies showed that allo-CTL response in MCF-7 cells was inhibited by prior treatment with estradiol/progesterone, but was amplified by their antagonists. The effects could be restored or further strengthened by the addition of anti-HLA-G antibodies. Our findings suggest that HLA-G may have potential clinical implications in diagnosis, prognosis, and immunotherapy of patients with breast cancer.
- 6 January 2010
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 17 (5) , 1459-1469
HLA-G Expression in Human Breast Cancer: Implications for Diagnosis and Prognosis, and Effect on Allocytotoxic Lymphocyte Response After Hormone Treatment In Vitro
The aim of this study is to investigate clinical implications of human leukocyte antigen-G (HLA-G) expression in breast cancer. HLA-G expression in 235 primary breast cancer tissues was investigated using immunohistochemistry, and plasma soluble HLA-G (sHLA-G) was measured in 44 breast cancer patients using a specific HLA-G enzyme-linked immunosorbent assay (ELISA). Effects of estradiol/progesterone and their antagonists tamoxifen/RU486 on HLA-G expression in cultured breast cancer MCF-7 cells were determined by real-time polymerase chain reaction (PCR) and the ELISA. Alterations of HLA-G expression by the hormone treatments on subsequent allocytotoxic lymphocyte (allo-CTL) response were also examined. In the study, approximately 66% of neoplasm lesions were identified to have positive HLA-G expression. This expression was significantly correlated with tumor size, nodal status, and clinical disease stage (P = 0.0001, 0.012, and 0.0001, respectively). Patients with positive HLA-G expression had a lower survival rate than those with negative expression (P < 0.028). Plasma sHLA-G levels were significantly higher in breast cancer patients than in healthy controls (P < 0.001), with the area under the receiver-operating characteristic (ROC) curve being 0.95. HLA-G expression in breast cancer MCF-7 cells was enhanced by estradiol/progesterone but reduced by their antagonists. Cytotoxicity studies showed that allo-CTL response in MCF-7 cells was inhibited by prior treatment with estradiol/progesterone, but was amplified by their antagonists. The effects could be restored or further strengthened by the addition of anti-HLA-G antibodies. Our findings suggest that HLA-G may have potential clinical implications in diagnosis, prognosis, and immunotherapy of patients with breast cancer.
- 12 June 2009
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 26 (7) , 751-758
Detection of survivin-expressing circulating cancer cells in the peripheral blood of patients with esophageal squamous cell carcinoma and its clinical significance
We previously demonstrated that the detection of circulating cancer cells (CCC) expressing survivin mRNA could provide valuable information for predicting recurrence in patients with breast, lung, gastric and colorectal carcinoma. The purpose of this study is to investigate whether the detection of survivin-expressing CCC in the peripheral blood is also useful for predicting recurrence in patients with esophageal squamous cell carcinoma (ESCC). Blood samples obtained from 108 ESCC patients and 75 healthy volunteers were quantitatively investigated by a technique that detected reverse transcription-polymerase chain reaction products based on a hybridization-enzyme linked immunosorbent essay. Not all of the patients were available for the follow-up study. Only 48 patients who were treated with similar adjuvant therapy regimens were available and followed-up for 33 months after the initial assay test. Survivin-expressing CCC were detected in 51 (47.2%) patients. The presence of survivin-expressing CCC was found to be significantly associated with depth of invasion, vascular invasion, nodal status, and disease stages (P = 0.032, 0.019, 0.018, and 0.001, respectively). During the follow-up period, patients who had positive survivin expressions had a higher relapse rate and a shorter survival time than those who had negative survivin expressions (P = 0.002 and 0.016, respectively). Examination of survivin-expressing CCC could provide valuable information in the prediction of haematogenous recurrence as well as in the prognosis of ESCC.
- 12 June 2009
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 26 (7) , 751-758
Detection of survivin-expressing circulating cancer cells in the peripheral blood of patients with esophageal squamous cell carcinoma and its clinical significance
We previously demonstrated that the detection of circulating cancer cells (CCC) expressing survivin mRNA could provide valuable information for predicting recurrence in patients with breast, lung, gastric and colorectal carcinoma. The purpose of this study is to investigate whether the detection of survivin-expressing CCC in the peripheral blood is also useful for predicting recurrence in patients with esophageal squamous cell carcinoma (ESCC). Blood samples obtained from 108 ESCC patients and 75 healthy volunteers were quantitatively investigated by a technique that detected reverse transcription-polymerase chain reaction products based on a hybridization-enzyme linked immunosorbent essay. Not all of the patients were available for the follow-up study. Only 48 patients who were treated with similar adjuvant therapy regimens were available and followed-up for 33 months after the initial assay test. Survivin-expressing CCC were detected in 51 (47.2%) patients. The presence of survivin-expressing CCC was found to be significantly associated with depth of invasion, vascular invasion, nodal status, and disease stages (P = 0.032, 0.019, 0.018, and 0.001, respectively). During the follow-up period, patients who had positive survivin expressions had a higher relapse rate and a shorter survival time than those who had negative survivin expressions (P = 0.002 and 0.016, respectively). Examination of survivin-expressing CCC could provide valuable information in the prediction of haematogenous recurrence as well as in the prognosis of ESCC.
- 1 February 2009
- Published by Elsevier in Lung Cancer
- Vol. 63 (2) , 284-290
Clinical significance of detecting survivin-expressing circulating cancer cells in patients with non-small cell lung cancer
- 1 February 2009
- Published by Elsevier in Lung Cancer
- Vol. 63 (2) , 284-290
Clinical significance of detecting survivin-expressing circulating cancer cells in patients with non-small cell lung cancer
- 31 December 2008
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 16 (3) , 780-782
In Reply: Circulating Cancer Cells and Their Clinical Use as Recurrence Markers for Gastric and Colorectal Cancer
- 31 December 2008
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 16 (3) , 780-782
In Reply: Circulating Cancer Cells and Their Clinical Use as Recurrence Markers for Gastric and Colorectal Cancer
- 4 November 2008
- Published by Springer Nature
- p. 157-174
Prediction of Metastasis and Recurrence of Breast Carcinoma: Detection of Survivin-Expressing Circulating Cancer Cells
- 4 November 2008
- Published by Springer Nature
- p. 157-174
Prediction of Metastasis and Recurrence of Breast Carcinoma: Detection of Survivin-Expressing Circulating Cancer Cells
- 1 August 2008
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 15 (11) , 3073-3082
Detection of Survivin-Expressing Circulating Cancer Cells (CCCs) in Peripheral Blood of Patients with Gastric and Colorectal Cancer Reveals High Risks of Relapse
We previously demonstrated that the detection of circulating cancer cells (CCCs) expressing survivin mRNA could provide valuable information for predicting metastasis and recurrence in breast cancer. The objective of this study was to investigate whether or not the detection of survivin expression in the peripheral blood could also have significant effects on the clinical outcomes of patients with gastric and colorectal cancer. Survivin-expressing CCCs in peripheral blood samples obtained from 55 gastric cancer patients, 86 colorectal cancer patients, and 87 healthy volunteers were quantitatively examined by using a RT-PCR ELISA. Its clinical significance was statistically evaluated. The CCCs in the peripheral blood samples were detected in 45.4% and 44.0% of gastric and colorectal cancer patients, respectively. The presence of survivin-expressing CCCs was found to be significantly associated with the degree of tumor penetration, nodal status, and disease stages for both types of cancers. During a follow-up period of 36 months, patients who had a positive detection at the time of the initial assay test had a higher relapse rate than those who had a negative detection. As well, survivin-expressing CCCs were statistically shown to be a significant and independent predictor for cancer recurrence. The detection of survivin-expressing CCCs was also demonstrated to be more accurate in terms of predicting recurrence than traditional detection methods such as plasma carcinoembryonic antigen (CEA) measurements. The detection of CCCs expressing survivin mRNA could be used to accurately identify gastric and colorectal cancer patients with high risks of relapse.
- 1 August 2008
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 15 (11) , 3073-3082
Detection of Survivin-Expressing Circulating Cancer Cells (CCCs) in Peripheral Blood of Patients with Gastric and Colorectal Cancer Reveals High Risks of Relapse
We previously demonstrated that the detection of circulating cancer cells (CCCs) expressing survivin mRNA could provide valuable information for predicting metastasis and recurrence in breast cancer. The objective of this study was to investigate whether or not the detection of survivin expression in the peripheral blood could also have significant effects on the clinical outcomes of patients with gastric and colorectal cancer. Survivin-expressing CCCs in peripheral blood samples obtained from 55 gastric cancer patients, 86 colorectal cancer patients, and 87 healthy volunteers were quantitatively examined by using a RT-PCR ELISA. Its clinical significance was statistically evaluated. The CCCs in the peripheral blood samples were detected in 45.4% and 44.0% of gastric and colorectal cancer patients, respectively. The presence of survivin-expressing CCCs was found to be significantly associated with the degree of tumor penetration, nodal status, and disease stages for both types of cancers. During a follow-up period of 36 months, patients who had a positive detection at the time of the initial assay test had a higher relapse rate than those who had a negative detection. As well, survivin-expressing CCCs were statistically shown to be a significant and independent predictor for cancer recurrence. The detection of survivin-expressing CCCs was also demonstrated to be more accurate in terms of predicting recurrence than traditional detection methods such as plasma carcinoembryonic antigen (CEA) measurements. The detection of CCCs expressing survivin mRNA could be used to accurately identify gastric and colorectal cancer patients with high risks of relapse.
- 1 November 2007
- Published by Elsevier in Lung Cancer
- Vol. 58 (2) , 267-274
Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer
- 1 November 2007
- Published by Elsevier in Lung Cancer
- Vol. 58 (2) , 267-274
Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer